<DOC>
	<DOC>NCT00327535</DOC>
	<brief_summary>This 4 arm study will assess the optimal starting dose of Mircera in the treatment of anemia in patients with non-small cell lung cancer receiving first line myelosuppressive chemotherapy. Patients will be randomized to receive either Mircera 6.3 micrograms/kg, 9 micrograms/kg or 12 micrograms/kg s.c. every 3 weeks or darbepoetin alfa according to the approved local label (either 6.75 micrograms/kg s.c. every 3 weeks, or 2.25 micrograms/kg every week). The anticipated time on study treatment is &lt;3 months and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>&gt;=18 years of age; stage III or IV nonsmall cell lung cancer receiving first line myelosuppressive chemotherapy; myelosuppressive chemotherapy scheduled for at least 9 weeks; anemia at screening visit. transfusion of red blood cells during the 4 weeks prior to first planned dose of study medication; iron deficiency anemia, or anemia caused by gastrointestinal bleeding; prior treatment with Mircera.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>